戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d the impact of primary graft dysfunction on bronchiolitis obliterans syndrome.
2 gnificant risk factor for the development of bronchiolitis obliterans syndrome.
3 rences were observed in the overall onset of bronchiolitis obliterans syndrome.
4  recipients is limited by the development of bronchiolitis obliterans syndrome.
5 y may improve lung function in patients with bronchiolitis obliterans syndrome.
6  the main risk factor for the development of bronchiolitis obliterans syndrome.
7 ection has been linked to the development of bronchiolitis obliterans syndrome.
8  defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.
9 fts due to acute rejection (AR) or developed bronchiolitis obliterans syndrome.
10                      Four patients developed bronchiolitis obliterans syndrome.
11 ociated with an increased risk of developing bronchiolitis obliterans syndrome.
12 n of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome.
13 ortality after lung transplantation (LTX) is bronchiolitis obliterans syndrome.
14 ng transplant patients prior to diagnosis of bronchiolitis obliterans syndrome.
15 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.
16 th chronic lung allograft rejection known as bronchiolitis obliterans syndrome.
17 he surviving study subjects remain free from bronchiolitis obliterans syndrome.
18      Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a
19 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.
20                                              Bronchiolitis obliterans syndrome, a common form of chro
21           Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin
22 epatitis C viral RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and
23              Infants and young children with bronchiolitis obliterans syndrome after lung transplanta
24 Thin-section CT studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months t
25 with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.
26  reported risk factor for the development of bronchiolitis obliterans syndrome, an important cause of
27 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat
28  study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after L
29 onic lung allograft rejection in the form of bronchiolitis obliterans syndrome and its histopathologi
30  distinct obstructive and restrictive forms: bronchiolitis obliterans syndrome and restrictive allogr
31  term comprises 2 major clinical phenotypes: bronchiolitis obliterans syndrome and restrictive allogr
32          Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr
33 valuates the current diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidem
34 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s
35 e hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.
36 nd the first 6 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.
37 hromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of n
38 tervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatme
39                Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for s
40 odel demonstrated that the increased risk of bronchiolitis obliterans syndrome associated with primar
41 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.
42                In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic
43 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic
44                                              Bronchiolitis obliterans syndrome (BOS) after lung trans
45  genetic polymorphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung trans
46                                              Bronchiolitis obliterans syndrome (BOS) after lung trans
47            Using log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft surviv
48 the internationally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follo
49  for chronic graft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttr
50                                 Freedom from bronchiolitis obliterans syndrome (BOS) at three years w
51 mplications occur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most c
52                                              Bronchiolitis obliterans syndrome (BOS) cases had lower
53                               Development of bronchiolitis obliterans syndrome (BOS) following lung t
54 unosuppressive therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsel
55 d for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine mode
56 plant operation on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive l
57 rentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung al
58  after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients
59 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients
60                                     The term bronchiolitis obliterans syndrome (BOS) is a clinical su
61                                              Bronchiolitis obliterans syndrome (BOS) is a condition o
62                                  Background: Bronchiolitis obliterans syndrome (BOS) is a late-onset
63                                              Bronchiolitis obliterans syndrome (BOS) is a major imped
64                           Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in u
65    Chronic allograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading c
66                                              Bronchiolitis obliterans syndrome (BOS) is the major lim
67                                              Bronchiolitis obliterans syndrome (BOS) is the major lim
68                                              Bronchiolitis obliterans syndrome (BOS) is the major obs
69                                              Bronchiolitis obliterans syndrome (BOS) is the most comm
70                                              Bronchiolitis obliterans syndrome (BOS) is the primary l
71  allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a
72 ll lung transplant recipients suffering from bronchiolitis obliterans syndrome (BOS) or restrictive a
73 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim
74                                              Bronchiolitis obliterans syndrome (BOS) remains the lead
75                                              Bronchiolitis obliterans syndrome (BOS) remains the main
76 -obliteration of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs afte
77                                              Bronchiolitis obliterans syndrome (BOS), a condition of
78 ement of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition pre
79 s limited by infectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chron
80                                              Bronchiolitis obliterans syndrome (BOS), a process of fi
81 w long-term survival and a high incidence of bronchiolitis obliterans syndrome (BOS), an inflammation
82 gnized, idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolit
83 ssion to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarke
84 tive (ELR(+)) CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect
85 n after lung transplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the
86 g to progressive airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major ca
87 man lung allograft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single m
88 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g
89                                              Bronchiolitis obliterans syndrome (BOS), pathognomonic f
90 allograft dysfunction (CLAD), and especially bronchiolitis obliterans syndrome (BOS), remain dominant
91                                              Bronchiolitis obliterans syndrome (BOS), the clinical co
92                                              Bronchiolitis obliterans syndrome (BOS), the major cause
93 n the fibro-obliterative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized
94 mputed tomography morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival we
95 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).
96 ejection or infection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).
97 mortality after lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).
98 to play an important role in the etiology of bronchiolitis obliterans syndrome (BOS).
99 hether it correlated with the development of bronchiolitis obliterans syndrome (BOS).
100 r lavage (BAL) fluid samples from LTxRs with bronchiolitis obliterans syndrome (BOS).
101 gnificant risk factor for the development of bronchiolitis obliterans syndrome (BOS).
102 r inhalation (L-CsA-i) for the prevention of bronchiolitis obliterans syndrome (BOS).
103  obliterans (BO), and its clinical correlate bronchiolitis obliterans syndrome (BOS).
104        The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).
105 splantation may contribute to development of bronchiolitis obliterans syndrome (BOS).
106 al owing to chronic allograft failure termed bronchiolitis obliterans syndrome (BOS).
107 e development of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).
108 all airway injury would increase the risk of bronchiolitis obliterans syndrome (BOS).
109 tation and is an established risk factor for bronchiolitis obliterans syndrome (BOS).
110 al outcomes, often due to the development of bronchiolitis obliterans syndrome (BOS).
111 tation remains limited by the development of bronchiolitis obliterans syndrome (BOS).
112 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve
113 enting chronic rejection of lung allografts (bronchiolitis obliterans syndrome [BOS]) and proinflamma
114 ce of all other causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered t
115 ar that patients may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictiv
116            A diagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191
117               Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS
118 transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).
119 , 41 patients remained STA, and 37 had CLAD (bronchiolitis obliterans syndrome, BOS, [n = 32] or rest
120 sinophilic BAL predisposed to development of bronchiolitis obliterans syndrome but particularly to re
121 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria
122   Acute rejection is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive bioma
123 d a shorter survival and an earlier onset of bronchiolitis obliterans syndrome compared with patients
124 pha as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomi
125                               This resembles bronchiolitis obliterans syndrome developed following hu
126  Adjustment for clinical variables including bronchiolitis obliterans syndrome did not change this re
127 aft-vs-host disease affects the lung tissue, bronchiolitis obliterans syndrome ensues.
128     Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of ac
129 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.
130    A trend, however, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was obser
131  survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV
132                                Patients with bronchiolitis obliterans syndrome had a higher risk of s
133                                              Bronchiolitis obliterans syndrome has been associated wi
134 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated
135 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific
136 enance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant rec
137 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec
138 ges to the progress of medical management of bronchiolitis obliterans syndrome include difficulties a
139 TF4 axis in the altered airway epithelium of bronchiolitis obliterans syndrome, including substantial
140 tion is associated with an increased risk of bronchiolitis obliterans syndrome independent of acute r
141                                              Bronchiolitis obliterans syndrome is a fibrotic occlusio
142                                              Bronchiolitis obliterans syndrome is a major problem for
143                                              Bronchiolitis obliterans syndrome is caused by a fibropr
144                                              Bronchiolitis obliterans syndrome is characterized by fi
145                                              Bronchiolitis obliterans syndrome is the leading cause o
146                       Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstac
147 ) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limit
148                                       Unlike bronchiolitis obliterans syndrome, it is not universally
149 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl
150 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea
151                     Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of
152 o be important in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severe
153 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri
154 was not a risk factor for the development of bronchiolitis obliterans syndrome or worse overall survi
155 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe
156 sease (P=0.54) nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).
157 sions in explanted lungs from four end-stage bronchiolitis obliterans syndrome patients was analyzed
158             Importantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in chil
159                                              Bronchiolitis obliterans syndrome remains the leading ca
160 genesis of chronic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucida
161 trated that respiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-
162              The remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared w
163                                              Bronchiolitis Obliterans Syndrome seriously reduces long
164 iated with a significantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: rela
165 acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univari
166 sponse to viruses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manif
167                                 Freedom from bronchiolitis obliterans syndrome was lower, and mortali
168 the association of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .
169 s in the six patients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion
170 hown to be implicated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered t

 
Page Top